Tyrosine kinase inhibitors – should we worry about cardiovascular complications?
Journal Title: OncoReview - Year 2017, Vol 7, Issue 2
Abstract
Small-molecular tyrosine kinase inhibitors constitute an effective therapeutic option in patients with hematologic malignancies and solid tumours. On the other hand, the significance of cardiovascular adverse events associated with their use is often emphasised. The events include arterial hypertension, heart failure, coronary disease/acute coronary syndromes, and long QT syndrome. The paper discusses the underlying mechanisms behind cardiovascular events associated with the treatment that involves tyrosine kinase inhibitors, and presents preventive and therapeutic options available in clinical practice. Awareness of the potential cardiovascular complications, regular follow-up, early diagnosis and initiation of appropriate treatment, combined with close collaboration with cardiology specialists, may enhance the benefits of long-term TKI therapy.
Authors and Affiliations
Katarzyna Styczkiewicz, Dariusz Sawka, Marek Styczkiewicz
Keywords
Related Articles
- EP ID EP189722
- DOI 10.24292/01.OR.300617.3
- Views 216
- Downloads 0
Quality of life in oncology and quality of life in course of molecularly targeted therapy in patients diagnosed with metastatic renal-cell carcinoma
Introduction of molecularly targeted agents into clinical practice has led to marked progress in pharmacotherapy of advanced renal cell carcinoma. There have been six drugs of the therapeutic class registered to date. Fu...
Cardiovascular complications of selected antibodies used in oncological immunotherapy
Immunotherapy supports other therapeutic methods and is an important element in the fight against cancer. Its main tasks include stimulation and guidance of the immune system to fight cancer, inhibition of the mechanisms...
PPARs and their role in cancer
Peroxisome proliferator activated receptors are members of a very common group of steroid nuclear receptors. The aim of the study was to present actual knowledge regarding the role of PPAR in cancerogenesis. Three types...
Carcinosarcoma of the uteri as a third diagnosed malignancy - case report and the review of treatment modality
Progress in metastatic renal cell carcinoma treatment is generally based on new registered drugs. This brings improvement of results but it also needs the choice of proper drug. The decision is especially important in in...
Kontrolowane placebo, z podwójnie ślepą próbą, prospektywne, randomizowane badanie skuteczności oktreotudu LAR w kontroli guza u chorych na guzy neuroendokrynne środkowej części prajelita z przerzutami: raport grupy badawczej PROMID
Wstęp: Analogi somatostatyny są wskazane w opanowywaniu objawów u chorych na żołądkowo-jelitowo-trzustkowe guzy neuroendokrynne (NETs). Zdolność analogów somatostatyny do kontrolowania wzrostu wysoko zróżnicowanych NETs...